Aromatase inhibitors

American Green (OTC:ERBB) Announces Increase of Revenue by 31% for its Online CBD Store

Retrieved on: 
Thursday, July 9, 2020
Entheogens, Euphoriants, Drugs, Appetite stimulants, Antiemetics, Aromatase inhibitors, Cannabinoid, Medical specialties, Tetrahydrocannabinol, Organ systems

When comparing the June 30th quarter to its previous quarter ending March 31, the company showed an increase in sales of 24%.

Key Points: 
  • When comparing the June 30th quarter to its previous quarter ending March 31, the company showed an increase in sales of 24%.
  • Additionally, the American Green CBD Store has separated itself from the pack by being responsive to market demand with respect to product selection.
  • To clarify, American Green currently provides one of the strongest and highest grade CBD Capsule strengths on the market.
  • The company also currently offers CBD Isolate , Water Soluble CBD and Broad Spectrum CBD (which includes a full range of cannabinoids and terpenes, without the presence of THC).

Emerald Bioscience Announces Awarding of Patent for Cannabidiol-Valine-Hemisuccinate in Japan

Retrieved on: 
Tuesday, June 2, 2020
Psychoactive drugs, Drugs, Entheogens, Antiemetics, Appetite stimulants, Aromatase inhibitors, Euphoriants, Tetrahydrocannabinol, Neurochemistry

This molecule, licensed from the University of Mississippi, was recently granted a similar patent in the United States.

Key Points: 
  • This molecule, licensed from the University of Mississippi, was recently granted a similar patent in the United States.
  • CBDVHS was reviewed and deemed not to be a controlled substance by the Drug Enforcement Agency (DEA) in 2019.
  • The recognition of the patent in Japan surrounding this bio-engineered, synthetic form of cannabidiol furthers EMBIs goal of achieving a parallel global patent footprint to the sister compound in our drug pipeline, the prodrug of THC, which was awarded a patent in Japan in 2015, commented Brian Murphy, MD, CEO of Emerald Bioscience.
  • Emerald's strategy is to clinically develop a number of proprietary biosynthetic compounds, alone or in combination with corporate partners.

Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial

Retrieved on: 
Friday, May 15, 2020
Hormones, Clinical medicine, Medicine, Aromatase inhibitors, Progonadotropins, RTT, Cancer treatments, Letrozole, Breast cancer, Tamoxifen, Adjuvant therapy, Aromatase

The Investigation on the Duration of Extended Adjuvant Letrozole (IDEAL) trial examined the Breast Cancer Index (BCI) HOXB13/IL17BR ratio (H/I) and its ability to predict benefit from extended endocrine therapy.

Key Points: 
  • The Investigation on the Duration of Extended Adjuvant Letrozole (IDEAL) trial examined the Breast Cancer Index (BCI) HOXB13/IL17BR ratio (H/I) and its ability to predict benefit from extended endocrine therapy.
  • The IDEAL study randomized patients to an additional 2.5 versus 5 years of extended endocrine therapy after completing 5 years of endocrine therapy with tamoxifen or aromatase inhibitors.
  • Findings from the study demonstrate that the Breast Cancer Index was significantly predictive of extended endocrine benefit from 5 versus 2.5 years of extended letrozole in patients that received any primary adjuvant therapy including combination tamoxifen/aromatase inhibitor or aromatase inhibitor monotherapy.
  • These findings add to the growing body of evidence demonstrating that Breast Cancer Index is the only commercially available genomic assay with predictive evidence to help inform the decision of extended endocrine therapy for HR+, early-stage breast cancer patients.

Tetra Bio-Pharma Receives FDA Orphan Drug Designation for Hepatocellular Carcinoma

Retrieved on: 
Wednesday, December 4, 2019
Medical specialties, Health, Drugs, Antiemetics, Appetite stimulants, Aromatase inhibitors, Entheogens, Euphoriants, Tetrahydrocannabinol, Hepatocellular carcinoma, Cannabinoid, Orphan drug

OTTAWA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (Tetra or the Company) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced it has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for delta-9-tetrahydrocannabinol (THC) in the treatment of hepatocellular carcinoma.

Key Points: 
  • OTTAWA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (Tetra or the Company) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced it has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for delta-9-tetrahydrocannabinol (THC) in the treatment of hepatocellular carcinoma.
  • We are very pleased to have received Orphan Drug Designation (ODD) from the FDA for THC.
  • This second ODD for cannabinoids demonstrates our innovation and successful drug development program that will soon include hepatocellular carcinoma," said Dr.
  • We intend to bring a modified formulation of Caumzfor hepatocellular carcinoma into clinical trials in Q1 2020.

Regulators Change Tact on CBD Use as Positive Clinical Results Mount

Retrieved on: 
Tuesday, October 29, 2019
Drugs, Antiemetics, Entheogens, Euphoriants, Appetite stimulants, Aromatase inhibitors, Tetrahydrocannabinol, Medical specialties, Organ systems

Regulators are more inclined to approve CBD because it does not cause any dependency or stimulate psychotropic effects, unlike THC.

Key Points: 
  • Regulators are more inclined to approve CBD because it does not cause any dependency or stimulate psychotropic effects, unlike THC.
  • As a result, CBD is having prominent impact on global markets as regulators move to use it as an alternative to traditionally prescribed medications.
  • In comparison, one of the highest CBD plants is Cannatonic, a strain with up to 12% CBD.
  • Moreover, positive general care and harvesting at a specific time can also result in higher CBD levels.

Regulators Change Tact on CBD Use as Positive Clinical Results Mount

Retrieved on: 
Tuesday, October 29, 2019
Drugs, Antiemetics, Entheogens, Euphoriants, Appetite stimulants, Aromatase inhibitors, Tetrahydrocannabinol, Medical specialties, Organ systems

Regulators are more inclined to approve CBD because it does not cause any dependency or stimulate psychotropic effects, unlike THC.

Key Points: 
  • Regulators are more inclined to approve CBD because it does not cause any dependency or stimulate psychotropic effects, unlike THC.
  • As a result, CBD is having prominent impact on global markets as regulators move to use it as an alternative to traditionally prescribed medications.
  • In comparison, one of the highest CBD plants is Cannatonic, a strain with up to 12% CBD.
  • Moreover, positive general care and harvesting at a specific time can also result in higher CBD levels.

Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies

Retrieved on: 
Thursday, September 12, 2019
Appetite stimulants, Entheogens, Euphoriants, Antiemetics, Medicine, Drugs, Medical specialties, Aromatase inhibitors, Dronabinol, Tetrahydrocannabinol, Cannabis, Cannabinoid

(OTC: MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its major investment company AXIM Biotechnologies, Inc .

Key Points: 
  • (OTC: MJNA) ("the Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its major investment company AXIM Biotechnologies, Inc .
  • ("AXIM Biotech" or "AXIM") (OTCQB: AXIM) has begun manufacturing its cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC).
  • "We look forward to the findings of AXIM's upcoming dronabinol chewing gum studies and understanding how it may help those undergoing chemotherapy."
  • AXIM Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products.

Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical Studies

Retrieved on: 
Tuesday, September 10, 2019
Appetite stimulants, Antiemetics, Aromatase inhibitors, Entheogens, Euphoriants, Drugs, Dronabinol, Medical specialties, Medicine, Chewing gum, Bioequivalence, Cannabinoid

In the coming months, AXIM intends to conduct a bioequivalence study between its chewing gum with dronabinol and an FDA-approved synthetic capsule.

Key Points: 
  • In the coming months, AXIM intends to conduct a bioequivalence study between its chewing gum with dronabinol and an FDA-approved synthetic capsule.
  • The Company plans to provide evidence that the Companys chewing gum with dronabinol can serve as an alternative to orally ingested dronabinol for the treatment of symptoms associated with chemotherapy.
  • AXIM plans to formulate its gum with various amounts of dronabinol, including 2.5 mg, 5 mg and 10 mg of dronabinol, for the study.
  • AXIM Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products.

RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit

Retrieved on: 
Monday, September 9, 2019
Appetite stimulants, Antiemetics, Aromatase inhibitors, Entheogens, Euphoriants, Dronabinol, Forward-looking statement, RespireRx, Medical specialties, Drugs, Organ systems

Our research and operational efforts are supported by our partnership with Noramco, Inc. for clinical and commercial supply of dronabinol.

Key Points: 
  • Our research and operational efforts are supported by our partnership with Noramco, Inc. for clinical and commercial supply of dronabinol.
  • We anticipate continuing this effort with potential collaborations and/or partnerships for formulation development, clinical development and ultimately commercialization.
  • RespireRx plans to develop a proprietary dronabinol formulation to optimize the dose and duration of action for treating OSA.
  • The Company does not intend to update or revise any forward-looking statements to reflect new information, future events or otherwise.

Harvest One Phase II Clinical Trials on Satipharm CBD GelPell® Published in Peer-Reviewed Medical Journal

Retrieved on: 
Tuesday, August 13, 2019
Drugs, Medical specialties, Appetite stimulants, Entheogens, Euphoriants, Antiemetics, Aromatase inhibitors, Medicine, Pharmacy, Cannabinoid, Tetrahydrocannabinol, Dose

Manufactured in Switzerland and EU GMP Certified, every 50mg GelPellcapsule has been clinically proven to improve the body's absorption of CBD and other cannabinoids.

Key Points: 
  • Manufactured in Switzerland and EU GMP Certified, every 50mg GelPellcapsule has been clinically proven to improve the body's absorption of CBD and other cannabinoids.
  • They are easy to take and contain a consistent and precise dose of CBD.
  • "The efficacy of Satipharm's CBD capsules as an add-on therapy in the treatment of pediatric, intractable epilepsy has been shown.
  • Satipharm CBD 50mg GelPell capsules are available in the UK through Health House who distribute to pharmacies and healthcare professionals.